Scott Power: ASX healthcare rises as AGM season comes to a close

Detailed summary

ASX healthcare sector rises alongside broader market for week ending November 13, 2026 as Clarity Pharmaceuticals secures an FDA approval. ... Read More The post Scott Power: ASX…

It’s closing time for ASX healthcare AGM season, leaving investors to digest company updates. Pic: Getty Images

Healthcare and life sciences expert Scott Power, a senior analyst at Morgans Financial for 29 years, and his team share their insights on the ASX healthcare sector for the week.

The ASX healthcare sector has seen a modest gain in the past week as AGM season comes to a close.

The S&P/ASX 200 Health Care index (ASX:XHJ) rose 0.85% for the past five days, slightly outperforming the benchmark S&P/ASX 200 (ASX:XJO), which was up 0.73%.

Morgans senior healthcare analyst Scott Power said this came as we head into a historically seasonally stronger period in the lead-up to Christmas.

“However, risk appetite remains patchy, and we’re not seeing much broad buying interest,” he said.

“All the information from the AGMs is now in the market and being digested by investors.”

Clarity Pharmaceuticals (ASX:CU6) came out of a trading halt and rose 23% on Thursday after prostate cancer imaging agent 64Cu-SAR-bisPSMA received Breakthrough Therapy designation from the US Food and Drug Administration (FDA).

Granted for the detection of recurrent prostate cancer (biochemical recurrence or BCR), Morgans healthcare analyst Iain Wilkie said it was the first Breakthrough Therapy designation awarded to a PSMA PET imaging agent.

Opening of the article, excerpted from Stockhead. To read the rest, open the article on the publisher's site.